|
|
||||||||
Nuclear Medicine Department, Kaiser Foundation Hospital, West Los Angeles, Los Angeles, California
Medical Physics Department, Southern California Permanente Medical Group, Los Angeles, California
Correspondence: For reprints contact: James T. Sprengelmeyer, MD, Nuclear Medicine Dept., Kaiser Foundation Hospital, West Los Angeles, 6041 Cadillac Ave., Los Angeles, CA 90034.
ABSTRACT
A 68-yr-old male with agnogenic myeloid metaplasia was given phosphorus-32-colloidal chromic phosphate intrapericardially for the treatment of malignant pericardial effusion. Technetium-99m-sulfur colloid was used to verify catheter placement and to visualize distribution within the pericardium. Estimated dosimetry for this mode of therapy is presented, and it is suggested that pericardial administration of phosphorus-32-colloidal chromic phosphate is the treatment of choice for malignant pericardial effusion.
This article has been cited by other articles:
![]() |
K. Reynen, U. Kockeritz, and R. H. Strasser Metastases to the heart Ann. Onc., March 1, 2004; 15(3): 375 - 381. [Full Text] [PDF] |
||||
![]() |
B. Maisch, A.D. Ristic, S. Pankuweit, A. Neubauer, and R. Moll Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin Eur. Heart J., October 2, 2002; 23(20): 1625 - 1631. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |